Horizon Therapeutics evaluates Krystexxa in combination with methotrexate to increase response rates and duration of therapy

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.

Read more

Eli Lilly and Company and Incyte Corporation: Positive Topline Results of RA-BEAM

Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.

Read more